These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9070287)

  • 1. A minimised hammerhead ribozyme with activity against interleukin-2 in human cells.
    Sioud M; Opstad A; Hendry P; Lockett TJ; Jennings PA; McCall MJ
    Biochem Biophys Res Commun; 1997 Feb; 231(2):397-402. PubMed ID: 9070287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of tRNA-embedded dimeric minizymes.
    Kuwabara T; Warashina M; Nakayama A; Ohkawa J; Taira K
    Nucleic Acids Symp Ser; 1997; (37):307-8. PubMed ID: 9586122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation of a catalytically active dimer by tRNA(Val)-driven short ribozymes.
    Kuwabara T; Warashina M; Orita M; Koseki S; Ohkawa J; Taira K
    Nat Biotechnol; 1998 Oct; 16(10):961-5. PubMed ID: 9788354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of several kinds of dimer minizyme: simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes.
    Kuwabara T; Amontov SV; Warashina M; Ohkawa J; Taira K
    Nucleic Acids Res; 1996 Jun; 24(12):2302-10. PubMed ID: 8710500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribozyme to human TGF-beta1 mRNA inhibits the proliferation of human vascular smooth muscle cells.
    Su JZ; Fukuda N; Hu WY; Kanmatsuse K
    Biochem Biophys Res Commun; 2000 Nov; 278(2):401-7. PubMed ID: 11097849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization in vitro and in vivo of hammerhead ribozymes directed against murine tumor necrosis factoralpha.
    MacKay SL; Tannahill CL; Auffenberg T; Ksontini R; Copeland EM; Moldawer LL
    Biochem Biophys Res Commun; 1999 Jul; 260(2):390-7. PubMed ID: 10403780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA.
    Scherr M; LeBon J; Castanotto D; Cunliffe HE; Meltzer PS; Ganser A; Riggs AD; Rossi JJ
    Mol Ther; 2001 Nov; 4(5):454-60. PubMed ID: 11708882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors altering ribozyme-mediated cleavage of tumor necrosis factor-alpha mRNA in vitro.
    Kisich KO; Freedland SJ; Erickson KL
    Biochem Biophys Res Commun; 1997 Jul; 236(1):205-11. PubMed ID: 9223453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catalytic activities of hammerhead ribozymes with a triterpenoid linker instead of stem/loop II.
    Sugiyama H; Hatano K; Saito I; Amontov S; Taira K
    FEBS Lett; 1996 Sep; 392(3):215-9. PubMed ID: 8774847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribozyme knockdown of the gamma-subunit of rod cGMP phosphodiesterase alters the ERG and retinal morphology in wild-type mice.
    Liu J; Timmers AM; Lewin AS; Hauswirth WW
    Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3836-44. PubMed ID: 16186371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evolution of the hammerhead ribozyme to a purine-specific ribozyme using mutagenic PCR with two nucleotide analogues.
    Kore AR; Vaish NK; Morris JA; Eckstein F
    J Mol Biol; 2000 Sep; 301(5):1113-21. PubMed ID: 10966809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of kit expression in P815 mouse mastocytoma cells by a hammerhead ribozyme.
    Shelburne CP; Huff TF
    Clin Immunol; 1999 Oct; 93(1):46-58. PubMed ID: 10497010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 TAR as anchoring site for optimized catalytic RNAs.
    Puerta-Fernandez E; Barroso-del Jesus A; Romero-López C; Berzal-Herranz A
    Biol Chem; 2003 Mar; 384(3):343-50. PubMed ID: 12715885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-beta s-ribozyme reduces beta s mRNA levels in transgenic mice: potential application to the gene therapy of sickle cell anemia.
    Alami R; Gilman JG; Feng YQ; Marmorato A; Rochlin I; Suzuka SM; Fabry ME; Nagel RL; Bouhassira EE
    Blood Cells Mol Dis; 1999 Apr; 25(2):110-9. PubMed ID: 10389593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of bcl-2 expression in lymphoma cells by bcl-2 ARE-targeted modified, synthetic ribozyme.
    Luzi E; Papucci L; Schiavone N; Donnini M; Lapucci A; Tempestini A; Witort E; Nicolin A; Capaccioli S
    Cancer Gene Ther; 2003 Mar; 10(3):201-8. PubMed ID: 12637941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-cleaving-ribozyme-mediated reduction of betaAPP in human rhabdomyosarcoma cells.
    Dolzhanskaya N; Conti J; Schwenk V; Merz G; Denman RB
    Arch Biochem Biophys; 2001 Mar; 387(2):223-32. PubMed ID: 11370845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2-specific hammerhead ribozyme.
    Bi F; Fan D; Hui H; Wang C; Zhang X
    Cancer Gene Ther; 2001 Nov; 8(11):835-42. PubMed ID: 11773973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase.
    Ludwig A; Saretzki G; Holm PS; Tiemann F; Lorenz M; Emrich T; Harley CB; von Zglinicki T
    Cancer Res; 2001 Apr; 61(7):3053-61. PubMed ID: 11306487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dependence on Mg2+ ions of the activities of dimeric hammerhead minizymes.
    Amontov S; Nishikawa S; Taira K
    FEBS Lett; 1996 May; 386(2-3):99-102. PubMed ID: 8647298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.